Bacterial endotoxin and current concepts in the diagnosis and treatment of endotoxaemia

References

1. Nikaido H, Nakae T. The outer membrane of gram-negative bacteria.. Adv Microb Physiol l979; 20:163–250
   [Google Scholar]
2. Donaldson D M, Roberts R R, Larsen H S, Tew J C. Interrelationship between serum beta-lysin, lysozyme, and the antibody-complement system in killing Escherichia coli.. Infect Immun 1974; 10:657–666
   [Google Scholar]
3. Brogden K A, Phillips M. The ultrastructural morphology of endotoxins and lipopolysaccharides.. Electron Microsc Rev 1988; 1:261–277
   [Google Scholar]
4. Flynn P M, Shenep J L, Gigliotti F, Davis D S, r W K. Immunolabelling of lipopolysaccharide liberated from antibiotic-treated Escherichia coli.. Infect Immun 1988; 56:2760–2762
   [Google Scholar]
5. Shenep J L, Flynn P M, Barrett F F, Stidham G L, Westenkirchner D F. Serial quantitation of endotoxemia and bacteremia during therapy for gram-negative bacterial sepsis. J Infect Dis 1988; 157:565–568
   [Google Scholar]
6. Rietschel E T, Schade U, Jensen M, Wollenweber H-W, Luderitz O, Greisman S G. Bacterial endotoxins: chemical structure, biological activity and role in septicaemia.. Scand J Infect Dis (Suppl) 1982; 31:8–21
   [Google Scholar]
7. Westphal O, Luderitz O, Galanos C, Mayer H, Rietschel E T. The story of bacterial endotoxin. Chedid L, Hadden J W, Spreafico F, Dukar P, Willoughby D. Advances in Immunopharmacology. Oxford: Pergamon Press; 1985; 13:
   [Google Scholar]
8. McCabe W R, Kreger B E, Johns M. Type-specific and cross-reactive antibodies in gram-negative bacteremia.. N Eng JMed 1972; 287:261–267
   [Google Scholar]
9. Tate W J, Douglas H, Braude A I, Wells W W. Protection against lethality of E. coli endotoxin with “0” antiserum.. Ann NY Acad Sci 1966; 133:746–762
   [Google Scholar]
10. Hitchcock P J, Leive L, Makela P H, Rietschel E T, Strittmatter W, Morrison D C. Lipopolysaccharide nomenclature-past, present, and future.. J Bacteriol
    [Google Scholar]
11. Griffis J M, Schneider H, Mandrel1 R E et al. Lipooligosaccharides : the principal glycolipids of the neisserial outer membrane.. Rev Infect Dis 1988; 10 (Suppl 2):
    [Google Scholar]
12. Brade H, Brade L, Rietschel E T. Structure-activity relationships of bacterial lipopolysaccharides (endotoxins).. Zentralbl Bakteriol Mikrobiol Hyg [A] 1988
    [Google Scholar]
13. Rietschel E T, Brade L, Brandenburg K et al. Chemical structure and biologic activity of bacterial and synthetic lipid A.. Rev Infect Dis 1987; 9 (Suppl5):S527–S536
    [Google Scholar]
14. Proctor R A, Will J A, Burhop K E, z C R. Protection of mice against lethal endotoxemia by a lipid A precursor.. Infect Immun 1986; 52:905–907
    [Google Scholar]
15. Kiener P A, Marek F, Rodgers G, Lin P F, Warr G, Desiderio J. Induction of tumor necrosis factor, IFNgamma, and acute lethality in mice by toxic and nontoxic forms of Lipid A.. JImmunol l988; 141:870–874
    [Google Scholar]
16. Morrison D C, n J L. Endotoxins and disease mechanisms. Annu Rev Med 1987; 38:417–432
    [Google Scholar]
17. Kreger B E, Craven D E, Carling P C, e W R. Gram-negative bacteremia. I11 Reassessment of etiology, epidemiology and ecology in 612 patients. Am J Med 1980; 68:332–343
    [Google Scholar]
18. Ispahani P, Pearson N J, Greenwood D. An analysis of community and hospital-acquired bacteraemia in a large teaching hospital in the United Kingdom.. Q J Med 1987; 63:427–440
    [Google Scholar]
19. Hamill R J, Maki D G. Endotoxin shock in man caused by gram-negative bacilli. Etiology, clinical features, diagnosis, natural history, and prevention.. Proctor R A. Handbook of endotoxin, vol4: Clinical aspects of endotoxin shock. Amsterdam: Elsevier; 1986; 55:
    [Google Scholar]
20. Bate C A W, Taverne J, Playfair J H L. Malarial parasites induce TNF production by macrophages.. Immunology
    [Google Scholar]
21. Jupin C, Anderson S, Damais C, Alouf J E, Parant M. Toxic shock syndrome toxin 1 as an inducer of human tumor necrosis factors and gamma interferon.. J Exp Med 1988; 167:752–761
    [Google Scholar]
22. van Deventer S J, ten Cate J W, t G N. Intestinal endotoxemia. Clinical significance.. Gastroenterology
    [Google Scholar]
23. Aoki K. A study of endotoxemia in ulcerative colitis and Crohn′s disease : 11.Experimental study.. Acta Med Okayama 1978; 32:207–216
    [Google Scholar]
24. Papa M, Halperin Z, Rubinstein E, Orenstein A, Gaffin S, Adar R. The effect of ischemia of the dog′s colon on transmural migration of bacteria and endotoxin.. J Surg Res 1983; 35:264–269
    [Google Scholar]
25. Walker R I. The contribution of intestinal endotoxin to mortality in hosts with compromised resistance: a review.. Exp Hematol l978; 6:172–184
    [Google Scholar]
26. Olcay I, Kitahama A, Miller R H, Drapanas T, Trejo R, Di Luzio N R. Reticuloendothelial dysfunction and endotoxemia following portal vein occlusion.. Surgery 1974; 75:64–70
    [Google Scholar]
27. Wellmann W, Fink P C, Schmidt F W. Whole-gut irrigation as antiendotoxinaemic therapy in inflammatory bowel disease.. Hepatogastroenterology 1984; 31:91–93
    [Google Scholar]
28. Palmer K R, Duerden B I, Holdsworth C D. Bacteriological and endotoxin studies in cases of ulcerative colitis submitted to surgery. Gut 1980; 21:851–854
    [Google Scholar]
29. Woodruff P W H, O'Carroll D I, Koizumi S, Fine J. Role of the intestinal flora in major trauma. Kass E H, Wolff S A. Bacterial lipopolysaccharides. Chicago: University of Chicago Press; 1973; 282
    [Google Scholar]
30. Brigham K L, Meyrick M. Endotoxin and lung injury. Am Rev Respir Dis 1986; 133:913–927
    [Google Scholar]
31. Harris R I, Stone P C W, Evans G R, Stuart J. Endotoxaemia as a cause of fever in immunosuppressed patients.. J Clin Pathol l984; 37:467–470
    [Google Scholar]
32. Shands J W, McKimmey C. Plasma endotoxin: increased levels in neutropenic patients do not correlate with fever. JInfect Dis 1989; 159:777–780
    [Google Scholar]
33. Scheifele D W, Olsen E M, Pendry M R. Endotoxinemia and thrombocytopenia during neonatal necrotizing enterocolitis.. Am J Clin Path01 1985; 83:227–229
    [Google Scholar]
34. Bailey M E. Endotoxin, bile salts and renal function in obstructive jaundice.. Br J Surg 1976; 63:774–778
    [Google Scholar]
35. Liehr H. Endotoxins and the pathogenesis of hepatic and gastrointestinal diseases.. Advances in internal medicine and pediatrics. New York: Springer-Verlag; 1982:; 117:
    [Google Scholar]
36. Moore R H, Lambert I A, Chia Y, Aber V R, Cohen J. Influence of endotoxin on graft-versus-host disease after bone marrow transplantation across major histocompatability barriers in mice.. Transplantation 1987
    [Google Scholar]
37. Tomosugi N, Cashman S J, Abbott F, Rees A J. Amplification of antibody mediated glomerular injury in vivo by tumour necrosis factor and interleukin 1.. Immunobiology 1987; 175:104
    [Google Scholar]
38. Morrison D C, Ryan J L. Bacterial endotoxins and host immune responses.. Dixon F J, Kumbel H G. Advances in immunology 28 New York: Academic Press; 1979293–449
    [Google Scholar]
39. Rapson N T. Biological and clinical effects of bacterial lipopolysaccharide.. Curr Opin Infect Dis 1988; 1:919–925
    [Google Scholar]
40. Rouzer C A, Cerami A. Hypertriglyceridemia associated with Trypanasoma brucei infection in rabbits: role of defective triglyceride removal.. Mol Biochem Parasitol
    [Google Scholar]
41. Kawakami M, Cerami A. Studies of endotoxin-induced decrease in lipoprotein lipase activity.. J Exp Med 1986; 234:470–474
    [Google Scholar]
42. Tracey K J, Beutler B, Lowry S F et al. Shock and tissue injury induced by recombinant human cachectin.. Science 1986; 234:470–474
    [Google Scholar]
43. Beutler B, Milsark I W, Cerami A. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin.. Science 1985; 229:869–871
    [Google Scholar]
44. Mathison J C, Wolfson E, Ulevitch R J. Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits.. JClin Invest 1988; 81:1925–1937
    [Google Scholar]
45. Tracey K J, Fong Y, Hesse D G et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia.. Nature 1987; 330:662–664
    [Google Scholar]
46. Ziegler E J. Tumor necrosis factor in humans.. N Eng J Med 1988; 318:1533–1535
    [Google Scholar]
47. Michie H R, Manogue K R, Spriggs D R et al. Detection of 82 K. F. BAYSTON AND J. COHEN circulating tumor necrosis factor after endotoxin administration. . N Eng JMed 1988; 318:1481–1486
    [Google Scholar]
48. Selby P, Hobbs S, Viner C et al. Tumour necrosis factor in man : clinical and biological observations.. Br J Cancer 1987; 56:803–808
    [Google Scholar]
49. Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease.. Lancet 1987; 1:355–357
    [Google Scholar]
50. Girardin E, Grau G E, Dayer J M, Roux-Lombard P, Lambert P H. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura.. N Eng JMed 1988; 319:397–400
    [Google Scholar]
51. Rothstein J L, Schreiber H. Synergy between tumor necrosis factor and bacterial products causes hemorrhagic necrosis and lethal shock in normal mice.. Proc Nut1 Acad Sci USA 1988; 85:607–611
    [Google Scholar]
52. Silva A T, Appelmelk B J, Buurman W A, Bayston K F, Cohen J. Survival of mice in experimental gram negative sepsis despite high levels of tumour necrosis factor (TNF) and interleukin 6 (IL6).. Twenty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy 1989 Abstract 1101
    [Google Scholar]
53. Andersen B M, Solberg O. Effect of benzylpenicillin in mice infected with endotoxin-liberating or non-liberating variant strains of Neisseria meningitidis.. Scand J Infect Dis 1984; 16:257–266
    [Google Scholar]
54. Roantree R J, Rantz L A. A study of the relationship of the normal bactericidal activity of human serum to bacterial infection. JClin Invest 1960; 39:72–81
    [Google Scholar]
55. Cohen J, McConell J S. Release of endotoxin from bacteria exposed to ciprofloxacin and its prevention with polymyxin B.. Eur J Clin Microbiol 1986; 5:13–17
    [Google Scholar]
56. Shenep J L, Mogan K A. Kinetics of endotoxin release during antibiotic therapy for experimental gramnegative bacterial sepsis. J Infect Dis 1984; 150:380–388
    [Google Scholar]
57. Rokke 0, Osterud B, Revhang A, Giercksky K. Increased serum endotoxin level after antibiotic administration in sepsis.. International Conference on Endotoxins I1 1987 Abstract 22
    [Google Scholar]
58. Tauber M G, Shibl A M, Hackbarth C J, Larrick J W, Sande M A. Antibiotic therapy, endotoxin concentration in cerebrospinal fluid, and brain edema in experimental Escherichia coli meningitis in rabbits. J Infect Dis 1987; 156:456–462
    [Google Scholar]
59. Jorgenson J H. Clinical applications of the Limulus amebocyte lysate test. Proctor R A. Handbook of endotoxin, vol4: Clinical aspects of endotoxin shock. Amsterdam: Elsevier; 1986; 1270:
    [Google Scholar]
60. Sturk A, ten Cate J W. Endotoxin testing revisited.. Eur J Clin Microbiol l985; 4:382–385
    [Google Scholar]
61. Cohen J, McConell J S. Observations on the measurement and evaluation of endotoxemia by a quantitative Limulus lysate microassay. JInfect Dis 1984; 150:916–924
    [Google Scholar]
62. Levin J, Tomasulo P A, Oser R S. Detection of endotoxin in human blood and demonstration of an inhibitor.. J Lab Clin Med 1970; 75:903–911
    [Google Scholar]
63. Eiden J, Yolken R H. C-Reactive protein and Limulus amebocyte lysate assay in diagnosis of bacterial meningitis. J Pediat 1986; 108:423–426
    [Google Scholar]
64. Prior R B, Spagna V A. Comparative evaluation of the tube and microdilution Limulus lysate techniques for rapid presumptive diagnosis of gonococcal urethritis in men.. J Clin Microbiol l980; 11:340–342
    [Google Scholar]
65. Nachum R, Berzofsky R N. Chromogenic Limulusamoebocyte lysate assay for rapid detection of gram-negative bacteriuria.. J Clin Microbiol l985; 21:759–763
    [Google Scholar]
66. Clayman M D, Raymond A, Colen D, Moffitt C, Wolf C, Neilson E G. The Limulus amebocyte lysate assay. A rapid and sensitive method for diagnosing early gramnegative peritonitis in patients undergoing continuous ambulatory peritoneal dialysis.. Arch Intern Med 1987; 147:337–340
    [Google Scholar]
67. Levin J, Poore T E, Young N S et al. Gram-negative sepsis: detection of endotoxemia with the Limulus Test. With studies of associated changes in blood coagulation, serum lipids, and complement.. Ann Intern Med 1972; 76:1–7
    [Google Scholar]
68. Elin R J. Clinical utility of the Limulus test with blood, CSF and synovial fluid.. Prog Clin Biol Res 1979; 29:279–292
    [Google Scholar]
69. Elin R J, Hosseini J. Clinical applications of the Limulus Amebocyte Lysate assay.. Cate J W, Buller H R, Sturk A, Levin J. Bacterial endotoxins : structure, biomedical significance, and detection with the Limulus amebocyte lysate test. New York: Alan R Liss; 1985307–324
    [Google Scholar]
70. Brandtzaeg P, Kierulf P, Ganstad P et al. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease.. JInfect Dis 1989; 159:195–204
    [Google Scholar]
71. Proctor R A. Role of antibody in the prevention and pathogenesis of endotoxin and gram-negative septic shock.. Proctor R A. Handbook of endotoxin, vol4: clinical aspects of endotoxin shock. Amsterdam: Elsevier; 1986; 161:
    [Google Scholar]
72. Ziegler E J, Douglas H, Sherman J E, Davis C E, Braude A I. Treatment of E. coli and Klebsiella bacteremia in agranulocytic animals with antiserum to a UDP-gal epimerase-deficient mutant.. JImmunol l973; 111:433–438
    [Google Scholar]
73. Young L S, Stevens P, Ingram J. Functional role of antibody against “core” glycolipid of Enterobacteriaceae.. J Clin Invest 1975; 56:850–861
    [Google Scholar]
74. Pollack M, Huang A I, Prescott R K et al. Enhanced survival in Pseudomonas aeruginosa septicemia associated with high levels of circulating antibody to Escherichia coli endotoxin core.. J Clin Invest 1983; 72:1874–1881
    [Google Scholar]
75. Ziegler E J, McCutchan J A, Fierer J et al. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli.. N Eng J Med 1982; 307:1225–1230
    [Google Scholar]
76. Baumgartner J D, Glauser M P, McCutchan J A et al. Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid.. Lancet 1985; 2:59–63
    [Google Scholar]
77. Chong K T, Huston M. Implications of endotoxin contamination in the evaluation of antibodies to lipopolysaccharides in a murine model of gram-negative sepsis. J Infect Dis 1987; 156:713–719
    [Google Scholar]
78. Siber G R, Kania S A, Warren H S. Cross-reactivity of rabbit antibodies to lipopolysaccharides of Escherichia coli J5 and other gram-negative bacteria.. J Infect Dis 1985; 152:954–964
    [Google Scholar]
79. Brade L, Brade H. A 28,000-dalton protein of normal mouse serum binds specifically to the inner core region of bacterial lipopolysaccharide.. Infect Immun 1985; 50:687–694
    [Google Scholar]
80. Wardle E N. Endotoxinaemia and the pathogenesis of acute renal failure.. Q J Med 1975; 44:389–398
    [Google Scholar]
81. Clemente C, Bosch J, Rodes J, Arroyo V, Mas A, Maragall S. Maragall S.Functiona1 renal failure and haemorrhagic gastritis associated with endotoxaemia in cirrhosis.. Gut 1977; 18:556–560
    [Google Scholar]
82. Maxwell A, Gaffin S L, Wells M T. Radiotherapy, Reeves D S, Geddes A M. Recent advances in endotoxaemia and nausea. Lancet 1986; 1:1148–1149
    [Google Scholar]
83. Stone R L, schilievert P M. Evidence for the involvement of endotoxin in toxic shock syndrome.. J Infect Dis 1987; 155:682–689
    [Google Scholar]
84. Cohen J. Endotoxin-significance, detection and treatment.. Reeves D S, Geddes A M. Recent advances in infection 3. Edinburgh, Churchill Livingstone. 1989; 131:
    [Google Scholar]